Ionis Pharmaceuticals, Inc. IONS
This picture changes. Follow Ionis Pharmaceuticals, Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow Ionis Pharmaceuticals, Inc. freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 30 Jul 2026
Latest news check: 1 Jul 2026
General analysis — not personal advice.
HOLD
6/10
Confidence
Existing position can be maintained pending further launch data and regulatory decisions.
Strong pipeline and cash balance are offset by high execution risk and recent clinical setbacks which support the hold signal.
Market sentiment
6/10
→
Trend: Stable
The market is divided between praise for sales growth and concern over clinical misses and execution risk.
Price context
The price at 54.04 USD sits 37.5 % below the 52-week high after the July setback, reflecting a revaluation where focus has shifted to commercial execution rather than pipeline potential.
Risk assessment
7/10
Dilution:
Low
Cash runway extends to positive cash flow in 2028
Jurisdiction:
Low
Primary operations in USA and Europe
Execution:
High
Unproven as fully owned commercial organization with multiple simultaneous launches
Cash flow:
24 mo
Recent changes
- ▲ Market cap rises about 27% to $13.34B, which does not meet the threshold to be reported as a large financial change under the rules.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (3) — follow the company freeAbout the company
Ionis Pharmaceuticals develops and commercializes antisense oligonucleotide medicines for neurological, metabolic and cardiovascular diseases. The company is transitioning from a royalty-based model to own commercialization with several recently launched products. Operations remain loss-making but supported by a strong cash position and pipeline.
Sector:
Biotech, RNA-targeted therapies
Type:
Biotech
Next report
15 Nov 2026
Q3
Catalysts
22 Sep 2026
Zilganersen PDUFA
High
26 Oct 2026
Bepirovirsen PDUFA
High
Nov 2026
Pelacarsen phase 3 data
Medium
Horizon:
Bull case
Strong Q2 report and early Tryngolza launch data provide momentum ahead of upcoming regulatory decisions.
Bear case
Clinical setback for eplontersen and continued negative results create uncertainty around execution.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| Tryngolza launch success | Weaker than expected sales uptake → revenue growth is delayed and the company remains loss-making longer. | Stronger than expected prescription trends → validates commercial model and accelerates revenue growth. |
| Zilganersen FDA decision | Rejection or delay → lost opportunity for first independent neurology launch and reduced pipeline diversification. | Approval → new revenue stream and confirmation of antisense platform breadth. |
We monitor these factors. Follow the company to get email when any of them hit.
Signal rationale (informational)
Strong pipeline and cash balance are offset by high execution risk and recent clinical setbacks which support the hold signal.
Recent news
- The Q2 report on 29 July showed revenues of 268 million USD beating estimates. At the same time it was announced that CSO Frank Bennett will retire in February 2027. The share price has fallen after the July clinical setback.
Key figures
Revenue
Q2 2026
USD 268M
EBITDA
TTM
USD -339M
Net income
Q2 2026
USD -115M
Cash
Q2 2026
USD 2.0B
Total debt
Q2 2026
USD 2.6B
Shares outstanding
Q2 2026
166M
EPS
Q2 2026
USD -0.69
Price & valuation
Last close
USD 55.42
Market Cap
USD 9.2B
1 week
+2.3 %
3 months
-28.6 %
12 months
+33.8 %
From 52w high
-35.9 %
From 52w low
+35.7 %
Exchange
NASDAQ
Type
Biotech
Sector
Biotech, RNA-targeted therapies
This picture changes. Follow Ionis Pharmaceuticals, Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.